CRL-40,941

CRL-40,941 (Fladrafinil) is a psychotonic and eugeroic related to Adrafinil, demonstrating similar but more potent effects than Adrafinil in animal models.1. As the bis(p-fluoro) derivative of adrafinil, CRL-40,941 is sometimes referred to as “Fladrafinil”.

Unlike Adrafinil, CRL-40,941 also possesses interesting anti-aggressive properties in animal testing1.

In mice, the LD-0 (maximum non-lethal dose) of CRL 40,941 is higher than 512 mg/kg, and the LD50 is higher than 1024 mg/kg1.

CRL 40,941 partially counteracted the hypothermia-inducing action of oxotremorine, did not provoke any major motorial deficit, did not increase the convulsant effects of electric shock, enabled a clear resumption of activity in the mouse habituated to its enclosure, improved motorial recovery in mice whose motility had been reduced by hypoxia, and counteracted sleep induced by barbital.1.

Adrafinil and the related family of eugeroics including Modafinil, CRL-40,941 and CRL-40,940 were originally invented in the late 1970’s as part of research carried out by the French Laboratoire L. Lafon, led by Dr. Michel Jouvet.

Compared to Adrafinil, CRL 40,941 was observed by the research team at Lafon to have similar psychotonic and eugeroic properties, but to have unique advantages: namely its antiaggressive properties and improved bioavailability by the oral route.

The research team at Lafon observed that “in fact, CRL 40,941,as a psychotonic agent, is clearly more effective by the oral route, in the rat and in man, than Adrafinil. From the clinical point of view, CRL 40,941 acts at doses which are half those of Adrafinil. Excellent results were obtained in man when CRL 40,941 was administered per os, at the rate of 2 to 3 capsules or tablets, (each containing 50mg of active ingredient) per day, particularly for 2 to 8 weeks in the treatment of hypersomnia and psychastenia.”